Seller record · Telehealth service

Basal

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 4 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The home and program pages refer only to a licensed compounding pharmacy partner, and the terms, privacy policy and refund policy name none. 3 more criteria also fail; see the table below.

At a glance

BasalTelehealth service

4/8criteria passed

Price: Compounded tirzepatide $149 for the first 4 weeks, then $299 every 4 weeks
Sells: compounded tirzepatide
FDA letters: None on file

Visit Basal See all eight dispositions

Telehealth service. Passes 4 of 8 criteria. Recorded against Standard v1.1.

A telehealth program selling compounded tirzepatide in a microdose plan and a weight loss plan at one price at every dose, with no membership fee, prescribed by clinicians of affiliated medical groups after an online eligibility intake.

Operating entity Basal Health LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Basal's GLP one page; Basal's terms
S2	Prescription gating	PASS	Basal's website; Basal's GLP one page
S3	Pharmacy identification	FAIL	Basal's GLP one page; Basal's terms; Basal's cancellation page
S4	Compounding disclosure	FAIL	Basal's GLP one page; Basal's website; Basal's terms
S5	Analytical documentation	FAIL	Basal's GLP one page; Basal's terms; Basal's cancellation page
S6	Business address	FAIL	Basal's contact page; Basal's terms; Basal's privacy page
S7	Price disclosure	PASS	Basal's GLP one page; Basal's website
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSThe program is physician-supervised and all treatment decisions are made by licensed clinicians, and the terms say care is given by independent providers of the medical groups affiliated with its licensed telehealth partners.Source: Basal's GLP one page; Basal's terms.

S2PASSThe program steps list eligibility screening on an intake form and clinician review first, and the program page says the patient is not charged until a licensed clinician approves treatment.Source: Basal's website; Basal's GLP one page.

S3FAILNo filling pharmacy is named. The home and program pages refer only to a licensed compounding pharmacy partner, and the terms, privacy policy and refund policy name none.Source: Basal's GLP one page; Basal's terms; Basal's cancellation page.

S4FAILThe program page describes the treatment as compounded tirzepatide made in licensed pharmacies, but no page, including the answers, the terms, the privacy policy and the refund policy, states that a compounded medication is not FDA-approved.Source: Basal's GLP one page; Basal's website; Basal's terms.

S5FAILNo certificate of analysis or lot document is published on the program page, the terms or the refund policy.Source: Basal's GLP one page; Basal's terms; Basal's cancellation page.

S6FAILThe seller prints no street address. The contact page and the footer give only email addresses and billing and clinical support telephone numbers, and the terms and privacy policy carry no postal address.Source: Basal's contact page; Basal's terms; Basal's privacy page.

S7PASSCompounded tirzepatide costs $149 for the first 4 weeks as an introductory price, then $299 every 4 weeks, at the same price at every dose and with no membership fee, for either the microdose or the weight loss plan.Source: Basal's GLP one page; Basal's website.

S8PASSNo FDA warning letter names Basal or Basal Health LLC, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded tirzepatide.

Other sellers of the same products

Who sells tirzepatide

Visit Basal

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.